Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lois Shepherd

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
The Lancet. Oncology|September 16, 2011
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient dataAngelo Di Leo, Christine Desmedt, John M S Bartlett, et al.
Journal of Medical Internet Research|March 7, 2025
Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation StudySamer El Kababji, Nicholas Mitsakakis, Elizabeth Jonker, et al.
JAMA|October 22, 2019
Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical TrialJeannie Callum, Michael E Farkouh, Damon C Scales, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 12, 2026
The Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable MutationsMerve Kaya, Lawrence H Lin, Jan Oosting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2010
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitorsJames N Ingle, Daniel J Schaid, Paul E Goss, et al.
Cancer|September 10, 2020
Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trialPrashanth Moku, Lois Shepherd, Suhail M Ali, et al.
Gynecologic Oncology|January 11, 2026
Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/ SHAPE trialSe Ik Kim, Jae-Weon Kim, Janice S Kwon, et al.
Journal of the National Cancer Institute|February 2, 2021
The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32Isabel Pimentel, Bingshu E Chen, Ana Elisa Lohmann, et al.
Blood|January 9, 2013
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 TrialA Keith Stewart, Suzanne Trudel, Nizar J Bahlis, et al.
The Oncologist|April 25, 2015
Defining breast cancer intrinsic subtypes by quantitative receptor expressionMaggie C U Cheang, Miguel Martin, Torsten O Nielsen, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
The Lancet. Oncology|September 16, 2011
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient dataAngelo Di Leo, Christine Desmedt, John M S Bartlett, et al.
Journal of Medical Internet Research|March 7, 2025
Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation StudySamer El Kababji, Nicholas Mitsakakis, Elizabeth Jonker, et al.
JAMA|October 22, 2019
Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical TrialJeannie Callum, Michael E Farkouh, Damon C Scales, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 12, 2026
The Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable MutationsMerve Kaya, Lawrence H Lin, Jan Oosting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2010
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitorsJames N Ingle, Daniel J Schaid, Paul E Goss, et al.
Cancer|September 10, 2020
Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trialPrashanth Moku, Lois Shepherd, Suhail M Ali, et al.
Gynecologic Oncology|January 11, 2026
Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/ SHAPE trialSe Ik Kim, Jae-Weon Kim, Janice S Kwon, et al.
Journal of the National Cancer Institute|February 2, 2021
The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32Isabel Pimentel, Bingshu E Chen, Ana Elisa Lohmann, et al.
Blood|January 9, 2013
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 TrialA Keith Stewart, Suzanne Trudel, Nizar J Bahlis, et al.
The Oncologist|April 25, 2015
Defining breast cancer intrinsic subtypes by quantitative receptor expressionMaggie C U Cheang, Miguel Martin, Torsten O Nielsen, et al.
Pageof 10